Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements align with label concepts for Otrexup (RA use, weekly SC administration approach, and pregnancy/monitoring themes). However, several administration/instruction and side-effect claims are not supported by the prescribing information excerpt provided (and some details appear inconsistent with what the excerpt explicitly states), lowering overall alignment.
Category Scores
Accurate Statements
Otrexup auto-injector is used for rheumatoid arthritis.
Supported by the label context provided under Warnings/Precautions (e.g., RA discussed) and Dosage/Administration section titled for Rheumatoid Arthritis (2.2).
Keep track of blood counts.
Supported indirectly by the label instruction to assess hematologic function and monitor bone marrow/liver/lung/kidney toxicities (2.2 and 5.1).
Unsupported Statements
Before each injection, remove the Otrexup auto-injector from the refrigerator and let it warm up in its original packaging at room temperature for about 15 to 30 minutes.
No storage/temperature or warm-up timing instructions are present in the provided label excerpts.
Remove the protective cap from the needle guard and the orange cover before injection.
No specific step-by-step auto-injector mechanism/parts instructions are included in the provided labeling excerpts.
Do not take the auto-injector out of its tray.
No tray/handling instruction is present in the provided label excerpts.
Choose the injection site on the stomach area (abdomen).
No specific injection-site selection (abdomen) is provided in the provided excerpts.
Pinch the skin between the thumb and index finger to create a fold before injection.
No skin-fold technique is present in the provided excerpts.
Place the Otrexup auto-injector against the pinched skin at a 90-degree angle.
No angle guidance is present in the provided excerpts.
Press the injection button firmly until you hear a click.
No click/button technique instruction is present in the provided excerpts.
Release the button immediately after hearing the click.
No click/release timing instruction is present in the provided excerpts.
Do not force the injection.
No instruction about not forcing the injection is present in the provided excerpts.
Massage the injection site for about 10 seconds to help spread the medication.
No massage duration/suggestion is present in the provided excerpts.
After removing the auto-injector from the skin, recap or cap it.
No recap/cap handling instruction is present in the provided excerpts.
Dispose of the used auto-injector according to the doctor's disposal instructions.
No disposal instructions for the auto-injector are present in the provided excerpts.
After administering the injection, replace the protective cap to keep the needle guard clean and covered until the next use.
No re-cap/needle guard cleanliness or “until the next use” instruction is present in the provided excerpts (and the label excerpt describes a single-dose auto-injector).
If a dose is missed, the doctor may suggest alternative administration methods such as the manual syringe that comes with Otrexup.
The provided excerpts do not address missed doses or switching to a manual syringe as an alternative administration method.
Inform the doctor if experiencing unusual side effects including skin lesions, dizziness, or difficulty swallowing.
The provided excerpts do not list these specific symptom examples as reportable adverse reactions.
Common side effects associated with Otrexup include skin reactions, mouth sores, diarrhea, and headache.
While diarrhea and ulcerative stomatitis are mentioned in warnings, the excerpt does not provide a “common side effects” list or include dizziness/headache or “skin reactions/mouth sores” as common adverse reactions.
Contradictions
Important Omissions
The label-supported key dosing frequency: Otrexup is “once-weekly subcutaneous use only.” (2.1)
Importance:
High
Explicit pregnancy-related instructions: verify pregnancy status before initiation (2.5/8.1) and contraindication in pregnancy (4/5.2).
Importance:
High
Monitoring beyond blood counts (the excerpt emphasizes assessment/monitoring of hematologic, hepatic, renal, and pulmonary function and toxicities).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Potential safety impact from unsupported or overly specific administration instructions and omission of key label elements present in the provided excerpts (especially once-weekly dosing and pregnancy contraindication/verification).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Step-by-step injection and side-effect/counseling details are not supported by the provided prescribing information excerpts; key dosing frequency and pregnancy contraindication/verification elements are omitted.
Suggested Improvement
Limit claims to dosing frequency (once-weekly SC only), pregnancy verification/contraception and pregnancy contraindication as shown in the excerpts, and general monitoring requirements from the label; remove or qualify unsupported device-use specifics and do not present an unsupported “common side effects” list.